Cargando…

Prevention of haematoma progression by tranexamic acid in intracerebral haemorrhage patients with and without spot sign on admission scan: a statistical analysis plan of a pre-specified sub-study of the TICH-2 trial

OBJECTIVE: We present the statistical analysis plan of a prespecified Tranexamic Acid for Hyperacute Primary Intracerebral Haemorrhage (TICH)-2 sub-study aiming to investigate, if tranexamic acid has a different effect in intracerebral haemorrhage patients with the spot sign on admission compared to...

Descripción completa

Detalles Bibliográficos
Autores principales: Ovesen, Christian, Jakobsen, Janus Christian, Gluud, Christian, Steiner, Thorsten, Law, Zhe, Flaherty, Katie, Dineen, Rob A., Bath, Philip M., Sprigg, Nikola, Christensen, Hanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5998558/
https://www.ncbi.nlm.nih.gov/pubmed/29895329
http://dx.doi.org/10.1186/s13104-018-3481-8
_version_ 1783331252633337856
author Ovesen, Christian
Jakobsen, Janus Christian
Gluud, Christian
Steiner, Thorsten
Law, Zhe
Flaherty, Katie
Dineen, Rob A.
Bath, Philip M.
Sprigg, Nikola
Christensen, Hanne
author_facet Ovesen, Christian
Jakobsen, Janus Christian
Gluud, Christian
Steiner, Thorsten
Law, Zhe
Flaherty, Katie
Dineen, Rob A.
Bath, Philip M.
Sprigg, Nikola
Christensen, Hanne
author_sort Ovesen, Christian
collection PubMed
description OBJECTIVE: We present the statistical analysis plan of a prespecified Tranexamic Acid for Hyperacute Primary Intracerebral Haemorrhage (TICH)-2 sub-study aiming to investigate, if tranexamic acid has a different effect in intracerebral haemorrhage patients with the spot sign on admission compared to spot sign negative patients. The TICH-2 trial recruited above 2000 participants with intracerebral haemorrhage arriving in hospital within 8 h after symptom onset. They were included irrespective of radiological signs of on-going haematoma expansion. Participants were randomised to tranexamic acid versus matching placebo. In this subgroup analysis, we will include all participants in TICH-2 with a computed tomography angiography on admission allowing adjudication of the participants’ spot sign status. RESULTS: Primary outcome will be the ability of tranexamic acid to limit absolute haematoma volume on computed tomography at 24 h (± 12 h) after randomisation among spot sign positive and spot sign negative participants, respectively. Within all outcome measures, the effect of tranexamic acid in spot sign positive/negative participants will be compared using tests of interaction. This sub-study will investigate the important clinical hypothesis that spot sign positive patients might benefit more from administration of tranexamic acid compared to spot sign negative patients. Trial registration ISRCTN93732214 (http://www.isrctn.com) ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13104-018-3481-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5998558
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-59985582018-06-25 Prevention of haematoma progression by tranexamic acid in intracerebral haemorrhage patients with and without spot sign on admission scan: a statistical analysis plan of a pre-specified sub-study of the TICH-2 trial Ovesen, Christian Jakobsen, Janus Christian Gluud, Christian Steiner, Thorsten Law, Zhe Flaherty, Katie Dineen, Rob A. Bath, Philip M. Sprigg, Nikola Christensen, Hanne BMC Res Notes Research Note OBJECTIVE: We present the statistical analysis plan of a prespecified Tranexamic Acid for Hyperacute Primary Intracerebral Haemorrhage (TICH)-2 sub-study aiming to investigate, if tranexamic acid has a different effect in intracerebral haemorrhage patients with the spot sign on admission compared to spot sign negative patients. The TICH-2 trial recruited above 2000 participants with intracerebral haemorrhage arriving in hospital within 8 h after symptom onset. They were included irrespective of radiological signs of on-going haematoma expansion. Participants were randomised to tranexamic acid versus matching placebo. In this subgroup analysis, we will include all participants in TICH-2 with a computed tomography angiography on admission allowing adjudication of the participants’ spot sign status. RESULTS: Primary outcome will be the ability of tranexamic acid to limit absolute haematoma volume on computed tomography at 24 h (± 12 h) after randomisation among spot sign positive and spot sign negative participants, respectively. Within all outcome measures, the effect of tranexamic acid in spot sign positive/negative participants will be compared using tests of interaction. This sub-study will investigate the important clinical hypothesis that spot sign positive patients might benefit more from administration of tranexamic acid compared to spot sign negative patients. Trial registration ISRCTN93732214 (http://www.isrctn.com) ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13104-018-3481-8) contains supplementary material, which is available to authorized users. BioMed Central 2018-06-13 /pmc/articles/PMC5998558/ /pubmed/29895329 http://dx.doi.org/10.1186/s13104-018-3481-8 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Note
Ovesen, Christian
Jakobsen, Janus Christian
Gluud, Christian
Steiner, Thorsten
Law, Zhe
Flaherty, Katie
Dineen, Rob A.
Bath, Philip M.
Sprigg, Nikola
Christensen, Hanne
Prevention of haematoma progression by tranexamic acid in intracerebral haemorrhage patients with and without spot sign on admission scan: a statistical analysis plan of a pre-specified sub-study of the TICH-2 trial
title Prevention of haematoma progression by tranexamic acid in intracerebral haemorrhage patients with and without spot sign on admission scan: a statistical analysis plan of a pre-specified sub-study of the TICH-2 trial
title_full Prevention of haematoma progression by tranexamic acid in intracerebral haemorrhage patients with and without spot sign on admission scan: a statistical analysis plan of a pre-specified sub-study of the TICH-2 trial
title_fullStr Prevention of haematoma progression by tranexamic acid in intracerebral haemorrhage patients with and without spot sign on admission scan: a statistical analysis plan of a pre-specified sub-study of the TICH-2 trial
title_full_unstemmed Prevention of haematoma progression by tranexamic acid in intracerebral haemorrhage patients with and without spot sign on admission scan: a statistical analysis plan of a pre-specified sub-study of the TICH-2 trial
title_short Prevention of haematoma progression by tranexamic acid in intracerebral haemorrhage patients with and without spot sign on admission scan: a statistical analysis plan of a pre-specified sub-study of the TICH-2 trial
title_sort prevention of haematoma progression by tranexamic acid in intracerebral haemorrhage patients with and without spot sign on admission scan: a statistical analysis plan of a pre-specified sub-study of the tich-2 trial
topic Research Note
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5998558/
https://www.ncbi.nlm.nih.gov/pubmed/29895329
http://dx.doi.org/10.1186/s13104-018-3481-8
work_keys_str_mv AT ovesenchristian preventionofhaematomaprogressionbytranexamicacidinintracerebralhaemorrhagepatientswithandwithoutspotsignonadmissionscanastatisticalanalysisplanofaprespecifiedsubstudyofthetich2trial
AT jakobsenjanuschristian preventionofhaematomaprogressionbytranexamicacidinintracerebralhaemorrhagepatientswithandwithoutspotsignonadmissionscanastatisticalanalysisplanofaprespecifiedsubstudyofthetich2trial
AT gluudchristian preventionofhaematomaprogressionbytranexamicacidinintracerebralhaemorrhagepatientswithandwithoutspotsignonadmissionscanastatisticalanalysisplanofaprespecifiedsubstudyofthetich2trial
AT steinerthorsten preventionofhaematomaprogressionbytranexamicacidinintracerebralhaemorrhagepatientswithandwithoutspotsignonadmissionscanastatisticalanalysisplanofaprespecifiedsubstudyofthetich2trial
AT lawzhe preventionofhaematomaprogressionbytranexamicacidinintracerebralhaemorrhagepatientswithandwithoutspotsignonadmissionscanastatisticalanalysisplanofaprespecifiedsubstudyofthetich2trial
AT flahertykatie preventionofhaematomaprogressionbytranexamicacidinintracerebralhaemorrhagepatientswithandwithoutspotsignonadmissionscanastatisticalanalysisplanofaprespecifiedsubstudyofthetich2trial
AT dineenroba preventionofhaematomaprogressionbytranexamicacidinintracerebralhaemorrhagepatientswithandwithoutspotsignonadmissionscanastatisticalanalysisplanofaprespecifiedsubstudyofthetich2trial
AT bathphilipm preventionofhaematomaprogressionbytranexamicacidinintracerebralhaemorrhagepatientswithandwithoutspotsignonadmissionscanastatisticalanalysisplanofaprespecifiedsubstudyofthetich2trial
AT spriggnikola preventionofhaematomaprogressionbytranexamicacidinintracerebralhaemorrhagepatientswithandwithoutspotsignonadmissionscanastatisticalanalysisplanofaprespecifiedsubstudyofthetich2trial
AT christensenhanne preventionofhaematomaprogressionbytranexamicacidinintracerebralhaemorrhagepatientswithandwithoutspotsignonadmissionscanastatisticalanalysisplanofaprespecifiedsubstudyofthetich2trial